Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

AMN

AMN Healthcare Launches $400M Senior Notes Offering

AMN Healthcare Services, Inc. (NYSE: AMN) has announced the launch of a $400.0 million offering of senior unsecured notes due 2031 by its wholly owned subsidiary, AMN Healthcare, Inc. The company plans to use the proceeds from this private offering, along with cash on hand and borrowings under its secured revolving credit facility, to redeem all of its $500.0 million aggregate principal amount of 4.625% senior unsecured notes due 2027 outstanding and to pay fees and expenses related to the offering.

The 2031 notes will be guaranteed by the company’s affiliates that guarantee its credit facilities. It is worth noting that the 2031 notes will be offered only to qualified institutional buyers and non-U.S. persons outside of the United States.

In 2024, AMN Healthcare's healthcare professionals reached nearly 15 million patients at more than 2,100 healthcare systems, including 87 percent of the top healthcare systems nationwide.

This announcement comes as AMN Healthcare continues to solidify its position as the leader and innovator in total talent solutions for healthcare, emphasizing its steadfast partnership approach to solving pressing workforce challenges and enabling better clinical outcomes and access to care. Following these announcements, the company's shares moved 2.19%, and are now trading at a price of $19.13. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS